AstraZeneca PLC
AstraZeneca PLC (AZN) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for AstraZeneca PLC (AZN), covering cash flow, earnings, and balance sheets.
AstraZeneca PLC (AZN) Income Statement & Financial Overview
Access detailed annual and quarterly income data for AstraZeneca PLC AZN financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $13.59B | $14.89B | $13.56B | $12.94B |
| Cost of Revenue | $2.23B | $2.73B | $3.08B | $2.18B |
| Gross Profit | $11.36B | $12.17B | $10.48B | $10.76B |
| Gross Profit Ratio | $0.84 | $0.82 | $0.77 | $0.83 |
| R&D Expenses | $3.16B | $4.68B | $3.12B | $3.008B |
| SG&A Expenses | $4.57B | $5.55B | $5.29B | $5.06B |
| Operating Expenses | $7.68B | $10.13B | $8.38B | $8.009B |
| Total Costs & Expenses | $9.91B | $12.86B | $11.46B | $10.19B |
| Interest Income | $84.00M | $64.00M | $183.00M | $100.00M |
| Interest Expense | $349.00M | $429.00M | $457.00M | $443.00M |
| Depreciation & Amortization | $1.28B | $2.34B | $1.82B | $1.28B |
| EBITDA | $5.08B | $4.43B | $4.10B | $4.12B |
| EBITDA Ratio | $0.37 | $0.30 | $0.30 | $0.32 |
| Operating Income | $3.67B | $2.04B | $2.11B | $2.75B |
| Operating Income Ratio | $0.27 | $0.14 | $0.16 | $0.21 |
| Other Income/Expenses (Net) | -$272.00M | -$370.00M | -$278.00M | -$349.00M |
| Income Before Tax | $3.40B | $1.67B | $1.83B | $2.40B |
| Income Before Tax Ratio | $0.25 | $0.11 | $0.13 | $0.19 |
| Income Tax Expense | $481.00M | $166.00M | $395.00M | $469.00M |
| Net Income | $2.92B | $1.50B | $1.43B | $1.93B |
| Net Income Ratio | $0.21 | $0.10 | $0.11 | $0.15 |
| EPS | $1.88 | $0.97 | $0.92 | $1.24 |
| Diluted EPS | $1.87 | $0.96 | $0.92 | $1.24 |
| Weighted Avg Shares Outstanding | $1.55B | $1.55B | $1.55B | $1.55B |
| Weighted Avg Shares Outstanding (Diluted) | $1.56B | $1.56B | $1.56B | $1.56B |
Over the last four quarters, AstraZeneca PLC's revenue moved from $12.94B in Q2 2024 to $13.59B in Q1 2025. Operating income in Q1 2025 was $3.67B, with a strong operating margin of 27%. Despite fluctuations in R&D and SG&A expenses, EBITDA for AstraZeneca PLC remained robust at $5.08B, reflecting operational efficiency. Net income rose to $2.92B, with an EPS of $1.88. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan